Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-09-29
2010-11-30
Woodward, Cherie M (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600
Reexamination Certificate
active
07842668
ABSTRACT:
The inventions include Apo2L/TRAIL formulations and methods of using such formulations. Lyophilized and crystal formulations of Apo-2L/TRAIL which are stable and have improved Apo2L/TRAIL trimer formation are provided. Methods of making Apo-2L/TRAIL formulations, as well as devices and kits containing such formulations are also provided.
REFERENCES:
patent: 5763223 (1998-06-01), Wiley et al.
patent: 6030945 (2000-02-01), Ashkenazi
patent: 6284236 (2001-09-01), Wiley et al.
patent: 6541606 (2003-04-01), Margolin et al.
patent: 0 417 563 (1991-03-01), None
patent: 0 870 827 (2004-03-01), None
patent: S62-283932 (1987-12-01), None
patent: H10-182481 (1998-07-01), None
patent: WO 97/01633 (1997-01-01), None
patent: WO 97/25428 (1997-07-01), None
patent: WO 98/28426 (1998-02-01), None
patent: WO 98/18921 (1998-05-01), None
patent: WO 98/32856 (1998-07-01), None
patent: WO 98/35986 (1998-08-01), None
patent: WO 98/41629 (1998-09-01), None
patent: WO 98/46643 (1998-10-01), None
patent: WO 98/46751 (1998-10-01), None
patent: 98/51793 (1998-11-01), None
patent: WO 99/02653 (1999-01-01), None
patent: WO 99/09165 (1999-02-01), None
patent: 99/06673 (1999-03-01), None
patent: WO 99/11791 (1999-03-01), None
patent: 99/01039 (1999-07-01), None
patent: WO 00/75191 (2000-12-01), None
patent: 00/17579 (2001-01-01), None
patent: WO 01/00832 (2001-01-01), None
patent: WO 0124814 (2001-04-01), None
patent: WO 01/24814 (2001-12-01), None
patent: WO 02/09755 (2002-02-01), None
Gueffroy, Ed. Buffers: A guide for the preparation and use of buffers in biological systems. Behring Diagnostics. Hoechst Corporation. 1975, pp. 10-11.
Hymowitz et al., (Biochemistry, Jan. 4, 2000; 39:633-640; cited in Applicant's IDS of May 27, 2007).
Armitage et al., “Molecular and Biological Characterization of a Murine Ligand for CD40”Nature357(6373):80-82 (1992).
Ashkenazi et al., “Safety and antitumor activity of recombinant soluble Apo2 ligand”Journal of Clinical Investigation104(2):155-162 (1999).
Banner et al., “Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNFβ Complex: Implications for TNF Receptor Activation”Cell73:431-445 (1993).
Bodmer et al., “Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL”Journal of Biological Chemistry275:20632-20637 (2000).
Brockhaus et al., “Identification of Two Types of Tumor Necrosis Factor Receptors on Human Cell Lines by Monoclonal Antibodies.”Proc. Natl. Acad. Sci. USA87:3127-3131 (1990).
Browning et al., “Lymphotoxin β, a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface”Cell72:847-856 (1993).
Cha et al., “2.8 A Resolution Crystal Structure of Human TRAIL, a Cytokine with Selective Antitumor Activity”Immunity11:253-261 (1999).
Chicheportiche et al., “TWEAK, A New Secreted Ligand in the Tumor Necrosis Factor Family that Weakly Induces Apoptosis”Journal of Biological Chemistry272(51):32401-32410 (1997).
Chinnaiyan et al., “Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy”Proc. Natl. Acad. Sci.97:1754-1759 (2000).
Craft et al.Clin Chem(Abstract only) 34(1):44-8 (Jan. 1988).
Darby and Creighton, “Disulfide Bonds in Protein Folding and Stability”Methods in Enzymology, B.A. Shirley, Totowa, NJ:Human Press Inc, Chapter 10, vol. 40:219-252 (1995).
Dealtry et al., “DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon-γ”European Journal of Immunology17:689-693 (1987).
Degli-Esposti et al., “Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family”Journal of Experimental Medicine186(7):1165-1170 (1997).
Degli-Esposti et al., “The Novel Receptor TRAIL-R4 Induces NF-κB and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain”Immunity7:813-820 (1997).
Gazitt, Y., “TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells”Leukemia13:1817-1824 (1999).
Gliniak and Le, “Tumor Necrosis Factor-related Apoptosis-inducing Ligand's Antitumor Activity in Vivo Is Enhanced by the Chemoptherapeutic Agent CPT-11”Cancer Research59:6153-6158 (1999).
Goodwin et al., “Molecular Cloning and Expression of the Type 1 and Type 2 Murine Receptors for Tumor Necrosis Factor.”Mol. Cell. Bio.11:3020-3026 (1991).
Griffith et al., “Monocyte-mediated Tumoricidial Activity via the Tumor Necrosis Factor-related Cytokine, TRAIL”Journal of Experimental Medicine189:1343-1353 (1999).
Gruss and Dower, “Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas”Blood85:3378-3404 (1995).
Hahne et al., “APRIL, A New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth”J Exp Med.188(6):1185-1190 (Sep. 21, 1998).
Hale et al., “Demonstration of in Vitro and in Vivo Efficacy of Two Biologically Active Human Soluble TNF Receptors Expressed inE. coli.” J. Cell. Biochem.(abstract only, suppl. 15F; P 424) p. 113 (1991).
Hohmann et al., “Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Facotr (TNFα)”Journal of Biological Chemistry264:14927-14934 (1989).
Hymowitz et al., “A unique zinc-binding site revealed by the high-resolution X-ray structure of homotrimeric Apo2L/TRAIL”Biochemistry39(4):633-640 (2000).
Hymowitz et al., “Triggering Cell Death: The Crystal Structure of Apo2L/TRAIL in a Complex with Death Receptor 5”Molecular Cell4(4):563-571 (1999).
Information Hyperlinked Over Proteins(IHOP) ,TNFSF10.
Itoh et al., “The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis.”Cell.66:233-243 (1991).
Jeremias et al., “TRAIL/Apo-2-ligand-induced apoptosis in human T cells”European Journal of Immunology28:143-152 (1998).
Jo et al., “Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand”Nature Medicine6(5):564-567 (2000).
Johnsen et al., “Regulation of Apo-2 Ligand/TRAIL Expression in NK cells-Involvement in NK Cell-Mediated Cytotoxicity”Cytokine11:664-672 (1999).
Johnson et al., “Expression and Structure of the Human NGF Receptor”Cell47:545-554 (1986).
Katsikis et al., “Interleukin-1β Converting Enzyme-like Protease Involvement in Fas-induced and Ativation-induced Peripheral Blood T Cell Apoptosis in HIV Infection. TNF-related Apoptotsis-inducing Ligand Can Mediate ACtivation-induced T Cell Death in HIV Infection”Journal of Experimental Medicine.
Keane, et al., “Chemotherapy Augments TRAIL-induced Apoptosis in Breast Cell Lines”Cancer Research59:734-741 (Feb. 1, 1999).
Kohno et al., “A Second Tumor Necrosis Factor Receptor Gene Product Can Shed a Naturally Occurring Tumor Necrosis Factor Inhibitor.”Proc. Natl. Acad. Sci. USA87:8331-8335 (1990).
Lawrence et al., “Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions”Nature Medicine7(4):383-385 (Apr. 2001).
Lewis et al., “Cloning and Expression of cDNAs for Two Distinct Murine Tumor Necrosis Factor Receptors Demonstrate One Receptor is Species Specific.”PNAS USA.88:2830-2834 (1991).
Loetscher et al., “Molecular cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor”Cell61:351-359 (1990).
MacFarlane et al., “Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL”Journal of Biological Chemistry272(41):25417-25420 (1997).
Mallet et al., “Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes—A Molecule Related to Nerve Growth Factor Receptor.
Flores Heather
Lin Tanya P.
Matthews Timothy C.
Pai Roger
Shahrokh Zahra
Genentech Inc.
Marschang Diane L.
Woodward Cherie M
LandOfFree
Apo-2 ligand/trail formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Apo-2 ligand/trail formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Apo-2 ligand/trail formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4208836